Iktos Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 71

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 14

Iktos General Information

Description

Developer of a drug discovery platform that combines generative AI and robotics to address inefficiencies in traditional drug development processes. The company's platform specializes in artificial intelligence and robotics applied to research in medicinal chemistry and new drug design, applied to chemical research, specifically medicinal chemistry, and new drug design developed several proprietary and innovative systems based on AI, helping researchers to identify drug candidates in their research and development program.

Contact Information

Website
www.iktos.ai
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 65 rue de Prony
  • 75017 Paris
  • France
+33 09
Primary Industry
Drug Discovery
Other Industries
Decision/Risk Analysis
Biotechnology
Other Healthcare Technology Systems
Corporate Office
  • 65 rue de Prony
  • 75017 Paris
  • France
+33 09

Iktos Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Iktos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Accelerator/Incubator Completed Generating Revenue
13. Accelerator/Incubator 06-Nov-2025 Completed Generating Revenue
12. Grant 20-Feb-2025 Completed Generating Revenue
11. Later Stage VC Cancelled Generating Revenue
10. Later Stage VC (Series A) 09-Mar-2023 Completed Generating Revenue
9. Grant 30-Nov-2021 Completed Generating Revenue
8. Early Stage VC 14-Jun-2019 Completed Generating Revenue
7. Accelerator/Incubator 12-Mar-2018 Completed Generating Revenue
6. Grant 01-Mar-2018 $1.11M $799K Completed Generating Revenue
5. Accelerator/Incubator 01-Jan-2018 $799K Completed Startup
To view Iktos’s complete valuation and funding history, request access »

Iktos Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary Shares
To view Iktos’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Iktos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform that combines generative AI and robotics to address inefficiencies in traditional
Drug Discovery
Paris, France
71 As of 2026

Hong Kong, Hong Kong
 

Oxford, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Iktos Competitors (3)

One of Iktos’s 3 competitors is InSilico Medicine Cayman, a Formerly VC-backed company based in Hong Kong, Hong Kong.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
InSilico Medicine Cayman Formerly VC-backed Hong Kong, Hong Kong
Exscientia Formerly VC-backed Oxford, United Kingdom
Numerion Labs Venture Capital-Backed San Francisco, CA
You’re viewing 3 of 3 competitors. Get the full list »

Iktos Patents

Iktos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026132447-A1 Polycyclic mthfd2 inhibitors and uses thereof Pending 20-Dec-2024
WO-2026083123-A1 Coupling a 3d generative model to a constrained conformation optimization module in a global reinforcement loop Pending 18-Oct-2024
EP-4459287-A1 Methods and tools for detecting the impact of compounds on protein, rna or dna interactions Pending 02-May-2023
US-20260309718-A1 Methods and tools for detecting the impact of compounds on protein, rna or dna interactions Pending 02-May-2023
WO-2024227864-A1 Methods and tools for detecting the impact of compounds on protein, rna or dna interactions Inactive 02-May-2023 G01N33/6845
To view Iktos’s complete patent history, request access »

Iktos Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Iktos Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
La French Tech Accelerator/Incubator
European Innovation Council Accelerator/Incubator Minority
Debiopharm Innovation Fund Corporate Venture Capital Minority
M Ventures Corporate Venture Capital Minority
Omnes Capital PE/Buyout Minority
You’re viewing 5 of 14 investors. Get the full list »

Iktos Acquisitions (1)

Iktos’s most recent deal was a Merger/Acquisition with Synsight. The deal was made on 08-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Synsight 08-Jul-2024 Merger/Acquisition Drug Discovery
To view Iktos’s complete acquisitions history, request access »

Iktos FAQs

  • When was Iktos founded?

    Iktos was founded in 2016.

  • Where is Iktos headquartered?

    Iktos is headquartered in Paris, France.

  • What is the size of Iktos?

    Iktos has 71 total employees.

  • What industry is Iktos in?

    Iktos’s primary industry is Drug Discovery.

  • Is Iktos a private or public company?

    Iktos is a Private company.

  • What is Iktos’s current revenue?

    The current revenue for Iktos is .

  • How much funding has Iktos raised over time?

    Iktos has raised $21M.

  • Who are Iktos’s investors?

    La French Tech, European Innovation Council, Debiopharm Innovation Fund, M Ventures, and Omnes Capital are 5 of 14 investors who have invested in Iktos.

  • Who are Iktos’s competitors?

    InSilico Medicine Cayman, Exscientia, and Numerion Labs are competitors of Iktos.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process